2. Search Result
Search Result
Results for "

CK1-IN-1

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

3

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111820
    CK1-IN-1

    		Casein Kinase p38 MAPK Cardiovascular Disease
    CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis .
    CK1-IN-1
  • HY-158975
    VRK1/CK1-IN-1

    		Casein Kinase Cancer
    VRK1/CK1-IN-1 (compound 36) is a dual inhibitor of vaccinia-related kinase 1 (VRK1) and casein kinase 1 (CK1), with the Ki of 37.9 nM for VRK1 and IC50s of 17 nM and 15 nM for δ and ε isoforms of CK1, respectively .
    VRK1/CK1-IN-1
  • HY-128433
    CK1-IN-3

    		Casein Kinase Neurological Disease
    CK1-IN-3 (compound 51) is a AC1 inhibitor with an IC50s 2.22 µM for CK-1δ .
    CK1-IN-3
  • HY-103383
    (R)-DRF053 dihydrochloride

    		CDK Casein Kinase Neurological Disease Cancer
    (R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC50s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .
    (R)-DRF053 dihydrochloride
  • HY-10324
    D4476
    5+ Cited Publications

    CaseIN KINase I INhibitor

    		 Casein Kinase Autophagy Apoptosis Cancer
    D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(CK1) with an IC50 value of 0.3 μM in vitro.
    D4476
  • HY-170860
    CK1δ/CK1ε liagnd-1

    		Casein Kinase Ligands for Target Protein for PROTAC Cancer
    CK1δ/CK1ε liagnd-1 is the ligand for CK1δ/CK1ε that can be used for synthesis of CK1 PROTAC degrader AH078 (HY-170859) as the ligand for target protein .
    CK1δ/CK1ε liagnd-1
  • HY-P11119
    CKS peptide

    		Casein Kinase Neurological Disease
    CKS peptide is a selective substrate peptide for CK1. CKS peptide can used to measure CK1 activity .
    CKS peptide
  • HY-169556
    CK1δ-IN-7

    		Casein Kinase Neurological Disease
    CK1δ-IN-7 (Compound 488) is the inhibitor for casein kinase 1δ (CK1δ) .
    CK1δ-IN-7
  • HY-P10606
    CK1tide

    		Biochemical Assay Reagents Others
    CK1tide is a substrate for casein kinase 1 (CK1) and can be used to assess CK1's in vitro catalytic activity by detecting whether CK1 can phosphorylate it .
    CK1tide
  • HY-173494
    GSK-3β/CK-1δ-IN-1

    		GSK-3 Casein Kinase Cancer
    GSK-3β/CK-1δ-IN-1 (8d) is a dual and blood-brain barrier penetrated GSK-3β / CK-1δ inhibitor, with IC50 values of 0.77 μM for GSK-3β and 0.57 μM for CK-1δ, respectively. GSK-3β/CK-1δ-IN-1 (8d) can be used in the research for neuroblastoma .
    GSK-3β/CK-1δ-IN-1
  • HY-110052
    TBCA
    1 Publications Verification

    		 Casein Kinase Cancer
    TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
    TBCA
  • HY-12443
    PF-5006739

    		Casein Kinase Neurological Disease
    PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .
    PF-5006739
  • HY-P5526
    CCK1-specific peptide substrate

    		Casein Kinase Others
    CCK1-specific peptide substrate is a biological active peptide. (This peptide sequence is based on rabbit muscle glycogen synthase with Ser7 phosphorylated. It is a peptide substrate for Casein Kinase I (CK1). CK1 phosphorylates Ser10. Ser7 is phosphorylated by PKA in vivo.)
    CCK1-specific peptide substrate
  • HY-100536
    IWP-3

    		Wnt Cancer
    IWP-3 is an potent inhibitor of Wnt production with an IC50 of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α .
    IWP-3
  • HY-153904
    Casein kinase 1δ-IN-5

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-5 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 47 nM. Casein kinase 1δ-IN-5 shows neuroprotective and anti-inflammatory properties both in vitro. Casein kinase 1δ-IN-5 has the potential for neurodegenerative diseases research.
    Casein kinase 1δ-IN-5
  • HY-145939
    BAY-888

    BRD5846

    		 Casein Kinase Cancer
    BAY-888 is a selective CK1α/CSNK1A1 (casein kinase 1α) ATP-competitive inhibitor (IC50: 4 nM@10 μM ATP; 63 nM@1 mM ATP). BAY-888 blocks the negative regulation of p53 and other signaling pathways by CK1α, induces apoptosis and inhibits proliferation of tumor cells. BAY-888 has shown inhibitory efficacy against cancers such as acute myeloid leukemia (AML) in PRISM barcoded cell line screening and can mimic the effects of shRNA-mediated CK1α knockdown. BAY-888 is primarily used for the development of anticancer drugs for p53 wild-type tumors and for the study of the mechanisms of CK1α-related signaling pathways .
    BAY-888
  • HY-153905
    Casein kinase 1δ-IN-6

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-6 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 23 nM. Casein kinase 1δ-IN-6 shows neuroprotective and anti-inflammatory properties both in vitro and in vivo. Casein kinase 1δ-IN-6 is a promising drug candidate and can be used for neurodegenerative diseases research.
    Casein kinase 1δ-IN-6
  • HY-18285
    Longdaysin

    		Wnt Casein Kinase ERK CDK Cancer
    Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of  5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .
    Longdaysin
  • HY-10456
    TAK-715
    Maximum Cited Publications
    13 Publications Verification

    		 p38 MAPK Casein Kinase Wnt Inflammation/Immunology
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .
    TAK-715
  • HY-108907
    SR-1277

    		Casein Kinase Cancer
    SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC50s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC50s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .
    SR-1277
  • HY-170859
    AH078

    		Casein Kinase Others
    AH078 (compound 37) is a PROTAC degrader that selectively targets CK1δ and CK1ε, and has low targeting for CK1α. AH078 consists of PROTAC linker (black part) Monomethyl octanoate (HY-W001958), target protein ligand (red part) (HY-170860) CK1δ/CK1ε liagnd-1 and E3 ligase ligand (blue part) E3 ligase Ligand 58 (HY-170861). Among them, E3 ligase ligand + linker can form a conjugate E3 Ligase Ligand-linker Conjugate 163 (HY-170862) .
    AH078
  • HY-18340
    (R)​-​CR8

    CR8, (R)-Isomer

    		 Molecular Glues CDK Apoptosis Neurological Disease Cancer
    (R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .
    (R)​-​CR8
  • HY-18340A
    (R)-CR8 trihydrochloride

    CR8, (R)-Isomer trihydrochloride

    		 Molecular Glues CDK Apoptosis Neurological Disease Cancer
    (R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .
    (R)-CR8 trihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: